Suggested remit: To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for adjuvant treatment of high-risk HER2-negative, BRCA-positive early or locally advanced breast cancer after chemotherapy and surgery.
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3893

Provisional Schedule

Committee meeting: 1 11 October 2022
Expected publication 03 January 2023

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Bristol Technology Assessment Group, University of Bristol


Key events during the development of the guidance:

Date Update
11 February 2022 Invitation to participate
29 October 2021 - 26 November 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 October 2021 In progress. Scoping

For further information on our processes and methods, please see our CHTE processes and methods manual